GlaxoSmithKline
GSK
#212
Rank
A$146.83 B
Marketcap
A$72.69
Share price
2.24%
Change (1 day)
34.44%
Change (1 year)

GlaxoSmithKline (GSK) - Cash on Hand

Cash on Hand as of September 2025 : A$6.68 Billion

According to GlaxoSmithKline's latest financial reports the company has A$6.68 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

GlaxoSmithKline - Cash on Hand chart (from 1996 to 2025)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31A$7.49 B-19.73%
2023-12-31A$9.33 B-31.6%
2022-12-31A$13.64 B77.27%
2021-12-31A$7.69 B-29.61%
2020-12-31A$10.93 B27.34%
2019-12-31A$8.58 B20.44%
2018-12-31A$7.13 B5.34%
2017-12-31A$6.77 B-20.67%
2016-12-31A$8.53 B-28.95%
2015-12-31A$12.01 B43.28%
2014-12-31A$8.38 B-19.04%
2013-12-31A$10.35 B56.12%
2012-12-31A$6.63 B-25.81%
2011-12-31A$8.94 B-5.74%
2010-12-31A$9.48 B-24.15%
2009-12-31A$12.50 B-12.38%
2008-12-31A$14.27 B38.44%
2007-12-31A$10.30 B36.52%
2006-12-31A$7.55 B-38.77%
2005-12-31A$12.33 B24.98%
2004-12-31A$9.86 B18.82%
2003-12-31A$8.30 B18.19%
2002-12-31A$7.02 B6.54%
2001-12-31A$6.59 B-31.22%
2000-12-31A$9.58 B98.35%
1999-12-31A$4.83 B-5.56%
1998-12-31A$5.11 B22.16%
1997-12-31A$4.19 B54.05%
1996-12-31A$2.72 B

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
AstraZeneca
AZN
A$12.30 B 84.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
Pfizer
PFE
A$22.53 B 237.14%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
A$27.39 B 309.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
A$14.66 B 119.45%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$15.72 B 135.17%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
A$3.31 B-50.43%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Dynavax Technologies
DVAX
A$0.97 B-85.42%๐Ÿ‡บ๐Ÿ‡ธ USA